The Effect of Liraglutide Versus Placebo When Added to Basal Insulin Analogues With or Without Metformin in Subjects With Type 2 Diabetes

Part of paid clinical trials in Phoenix, Arizona.

Sponsor
Novo Nordisk A/S
Study ID
NCT01617434
Phase
PHASE3
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • liraglutide — DRUG
    Maximum 1.8 mg administered s.c. (subcutaneously, under the skin) once daily in addition to the subject's stable pre-trial basal insulin analogue regimen plus/minus metformin.
  • placebo — DRUG
    Placebo administered s.c. (subcutaneously, under the skin) once daily in addition to the subject's stable pre-trial basal insulin analogue regimen plus/minus metformin.

Study Details

This trial is conducted in Asia, Europe and North and South America. The aim of the trial is to investigate the effect of liraglutide versus placebo when added to basal insulin analogues with or without metformin in subjects with type 2 diabetes.

Key Dates

Start date
Sep 30, 2012
Status verified
Jan 2017
Primary completion
Oct 31, 2013
Completion
Oct 31, 2013

Study Design

Enrollment
451 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Liraglutide
  • Placebo Comparator: Placebo

Primary Outcome Measure

Change in Glycosylated Haemoglobin (HbA1c) From Baseline to Week 26 [ Time Frame: Week 0 to Week 26 ]

Locations (31)

FacilityCityStateZIPSite coordinators
Novo Nordisk Investigational SitePhoenixArizona85020-
Novo Nordisk Investigational SiteAnaheimCalifornia92801-
Novo Nordisk Investigational SiteFresnoCalifornia93726-
Novo Nordisk Investigational SiteLos AngelesCalifornia90057-
Novo Nordisk Investigational SiteSan MateoCalifornia94401-
Novo Nordisk Investigational SiteSan RamonCalifornia94583-
Novo Nordisk Investigational SiteTustinCalifornia92780-7045-
Novo Nordisk Investigational SiteVenturaCalifornia93003-
Novo Nordisk Investigational SiteWalnut CreekCalifornia94598-
Novo Nordisk Investigational SiteKissimmeeFlorida34741-
Novo Nordisk Investigational SiteGurneeIllinois60031-
Novo Nordisk Investigational SiteGreenfieldIndiana46140-
Novo Nordisk Investigational SiteLexingtonKentucky40503-
Novo Nordisk Investigational SiteMetairieLouisiana70002-
Novo Nordisk Investigational SiteRockvilleMaryland20852-
Novo Nordisk Investigational SiteMethuenMassachusetts01844-
Novo Nordisk Investigational SiteOmahaNebraska68114-
Novo Nordisk Investigational SiteNewingtonNew Hampshire03801-
Novo Nordisk Investigational SiteGreensboroNorth Carolina27401-1023-
Novo Nordisk Investigational SiteMcMurrayPennsylvania15317-
Novo Nordisk Investigational SiteSpartanburgSouth Carolina29303-
Novo Nordisk Investigational SiteKingsportTennessee37660-
Novo Nordisk Investigational SiteDallasTexas75230-
Novo Nordisk Investigational SiteSan AntonioTexas78215-
Novo Nordisk Investigational SiteSan AntonioTexas78224-
Novo Nordisk Investigational SiteSugarlandTexas77478-
Novo Nordisk Investigational SiteSalt Lake CityUtah84107-
Novo Nordisk Investigational SiteMidlothianVirginia23114-
Novo Nordisk Investigational SiteRichmondVirginia23219-
Novo Nordisk Investigational SiteRentonWashington98057-
Novo Nordisk Investigational SiteMartinsburgWest Virginia25401-

Find similar trials in Phoenix, AZ

By condition
Type 2 diabetes
By specialty
EndocrinologyMetabolic healthWeight loss
By research site
Novo Nordisk Investigational Site· Phoenix, AZNovo Nordisk Investigational Site· Anaheim, CANovo Nordisk Investigational Site· Fresno, CANovo Nordisk Investigational Site· Los Angeles, CANovo Nordisk Investigational Site· San Mateo, CANovo Nordisk Investigational Site· San Ramon, CA

Related Studies